Dallas, Texas 01/16/2014 (FINANCIALSTRENDS) – ImmunoCellular Therapeutics, Ltd.(NYSEMKT:IMUC) has been in the business of developing therapies, using its core biotechnology based techniques which promote immunology solutions. The company has, in the past year testing one of its lead candidates for the treatment of a rare type of brain tumor called the Glioblastoma multiforme or GBM. Though the vaccine – ICT-107- which is delivered through dendritic cells. Currently, patients who have been diagnosed with this condition, and have completed resection as well as chemoradiation options are under consideration.
ImmunoCellular Therapeutics, Ltd.(NYSEMKT:IMUC) had noted that there was in increase in progression-free survival given the quality of statistical significance. It was found that GBM carrying patients showed difference time lines of survival for ICT as well as placebo controlled study. It was found that when placebo was used, ICT-107 was found to have two months additional time line.
GMB is considered to be one of the fast spreading cancer conditions. Unfortunately this rare form of cancer is known to cause death in less than 3 to 4 months of first detection. The tumor which progresses to malignancy very rapidly boasts of higher median survival time with the use of some therapies as currently available in the market- Temozolomide, which is product marketed by Merck and company. This drug, though known to have been introduced back in 2005, is the last know drugs used in treating GMB. The drug is known to improve the median survival point for patients who have just been diagnosed as GBM, from the accepted 12.1 months to over 14.6 months.
The vaccine therapy provider for GBM and other turmors has 494,106 volume and $54.81 billion market cap. The US company has a 52 week high of $4.00 and 52 week low of $0.65. EPS is0 0.05.The stock prices were found to rally as ICT-121, Immunocellular Therapeutics second vaccine showed that the Phase I study had administered it to the first patient.